The antiviral drugs market is poised for steady expansion, projected to reach a valuation of USD 89.68 billion by 2033, up from USD 61.42 billion in 2023, growing at a CAGR of 3.9% over the forecast period . This growth is driven by increasing cases of viral infections, including HIV/AIDS, hepatitis B and C, and influenza, which are driving demand for antiviral medications. Innovations in antiviral drug manufacturing are leading to significant cost reductions. For instance, a 19-year-old developed a more efficient and cost-effective method to produce the antiviral drug galidesivir, reducing the cost from $75 to $12.50 per gram . Such advancements are expected to influence the overall pricing trends in the antiviral additives market.